Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients

Blood

Volumn 111, Issue 8, 2008, Pages 4209-4219

  Cassani, Barbara ^a   Mirolo, Massimiliano ^a   Cattaneo, Federica ^a   Benninghoff, Ulrike ^a   Hershfield, Michael ^b   Carlucci, Filippo ^c   Tabucchi, Antonella ^c   Bordignon, Claudio ^d   Roncarolo, Maria Grazia ^a,d   Aiuti, Alessandro ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SIENA   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE DEAMINASE; BUSULFAN; CALCIUM ION; CD28 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEOXYADENOSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE ZAP 70; T LYMPHOCYTE RECEPTOR; CYTOKINE; DEOXYADENOSINE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ADA GENE; ADENOSINE DEAMINASE DEFICIENCY; ADENOSINE DEAMINASE DEFICIENCY SEVERE COMBINED IMMUNODEFICIENCY; APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INFANT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ENZYME SPECIFICITY; ENZYMOLOGY; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; INTRACELLULAR SPACE; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ADENOSINE DEAMINASE; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOKINES; DEOXYADENOSINES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; INTRACELLULAR SPACE; LYMPHOCYTE ACTIVATION; PHOSPHORYLATION; RECEPTOR, ADENOSINE A2A; RECEPTORS, ANTIGEN, T-CELL; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 43249112042     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-05-092429     Document Type: Article

References (58)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2:1067-1069.
2. Hirschhorn R, RoegnerV, Rubinstein A, Papa-georgiou P. Plasma deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in an adenosine deaminase-deticient child. J Clin Invest. 1980;65:768-771.
3. Buckley RH. Schiff Rl, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378-387.
4. Hirschhorn R. Immunodeficiency disease due to deficiency of adenosine deaminase. In: Ochs H, Smith C, Puck J, eds. Primary Immunodeficiency Diseases. New York, NY: Oxford Univ. Press, 1999.
5. Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet. 1998;63:1049-1059.
6. Hershfield MS. Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine and adenine arabinoside: a basis for direct toxic effects of analogs of adenosine. J Biol Chem. 1979;254:22-25.
7. Hershfield MS, Kurtzberg J, Harden E, Moore JO, Whang-Peng J, Haynes BF. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2′-deoxycoformycin. Proc Natl Acad Sci USA. 1984;81:253-257.
8. Benveniste P, Cohen A. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1995;92:8373-8377.
9. Van De Wiele CJ, Vaughn JG, Blackburn MR, et al. Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation. J Clin Invest. 2002;110:395-402.
10. Malacarne F, Benicchi T, Notarangelo LD, et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol. 2005;35:3376-3386.
11. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol. 2004;22:657-682.
12. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest. 2001;108:131-141.
13. Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, LeaT, JahnsenT. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem. 1992;267:15707-15714.
14. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997;90:1600-1610.
15. Lappas CM, Rieger JM, Linden J. A2Aadenosine receptor induction inhibits IFN-gamma production in murine CD4+ Tcells. J Immunol. 2005;174:1073-1080.
16. Kohn DB, Weinberg, K.I. Adenosine deaminase deficiency: the genes of primary immunodeficiency. In: Windows on the Immune System and Prospect for the Gene Therapy. Bethesda, MD:National Institutes of Health, 1996.
17. Ozsahin H, Arredondo-Vega FX, Santisteban I. et al. Adenosine deaminase deficiency in adults. Blood. 1997;89:2849-2855.
18. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361:553-560.
19. Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest. 1981;68:1387-1393.
20. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589-596.
21. Buckley RH. Molecular defects in human severecombined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004:22:625-655.
22. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.
23. Aiuti A, Gassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117:2233-2240.
24. Carlucci F, Tabucchi A, Aiuti A, et al. Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. Clin Chem. 2003;49:1830-1838.
25. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994:179:493-502.
26. Aiuti A, Vai S. Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002:8:423-425.
27. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal. 2004;16:1211-1227.
28. Ruland J, MakTW. Transducing signals from antigen receptors to nuclear factor kappaB. Immunol Rev. 2003;193:93-100.
29. Hershfield MS. Combined immune deficiency due to purine enzyme defects. In: Stiehm ER, Ochs H, Winkelstein J, eds. Immunologic Disorders in Infants & Children, ed 5. Philadelphia, PA: Elsevier Saunders, 2004:480.
30. Zocchi C, Ongini E, Conti A, et al. The nonxan-thine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol ExpTher. 1996;276:398-404.
31. Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M. [3H]CGS 21680, aselectiveA2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol ExpTher. 1989;251:888-893.
32. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal. 2002;14: 99-108.
33. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal. 2002;14:1-9.
34. Gjertsen BT, Mellgren G, Often A, et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture: basal cAMP-kinase activity modulates interleukin-1 beta action. J Biol Chem. 1995;270:20599-20607.
35. Kizaki H, Suzuki K, TadakumaT, Ishimura Y. Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage. J Biol Chem. 1990;265:5280-5284.
36. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75:377-383.
37. Jorritsma PJ, Brogdon JL, Bottomry K. Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J Immunol. 2003;170:2427-2434.
38. Barton K, Muthusamy N, Chanyangam M, Fischer C, Clendenin C, Leiden JM. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature. 1996;379:81-85.
39. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663.
40. Blanchet F, Cardona A, Letimier FA, Hershfield MS, Acuto O. CD28 costimulatory signal induces protein arginine methylation in T cells. J Exp Med. 2005;202:371-377.
41. Hershfield MS, Kredich NM, Ownby DR, Ownby H, Buckley R. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2′-deoxyadenosine in adenosine deaminase-deficient patients. J Clin Invest. 1979;63:807-811.
42. Hershfield MS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In:ScriverCR, BeaudetAL, SlyWS, Valle D, ed.The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York. NY: McGraw-Hill; 2001:2585-2625.
43. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol. 2005;35:25-30.
44. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol.2001 ;61:443-448.
45. Skalhegg BS, Tasken K, Hansson V, Huitfeldt HS, JahnsenT, LeaT. Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science. 1994;263:84-87.
46. Vang T, Torgersen KM. Sundvold V. et al. Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through theTcell receptor. J Exp Med. 2001 ;193:497-507.
47. Ramstad C, Sundvold V, Johansen HK, LeaT. cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating ser-43 of raf-1 in the MAPK/ERK pathway. Cell Signal. 2000;12:557-563.
48. Badou A, Savignac M, Moreau M, et al. Weak TCR stimulation induces a calcium signal that triggers IL-4 synthesis, strongerTCR stimulation induces MAP kinases that control IFN-gamma production. Eur J Immunol. 2001 ;31:2487-2496.
49. Koike T Yamagishi H, Hatanaka Y et al. A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of Tcell activation. J Biol Chem. 2003;278:15685-15692.
50. Graves LM, Guy HI, Kozlowski P, et al. Regulation of carbamoyl phosphate synthetase by MAP kinase. Nature. 2000;403:328-332.
51. Madrenas J, Wange RL, Wang JL. Isakov N, Samelson LE, Germain RN. Zeta phosphorylation without ZAP-70 activation induced byTCR antagonists or partial agonists. Science. 1995;267:515-518.
52. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science. 1996;271:1276-1278.
53. Mondino A, Whaley CD, DeSilva DR, Li W, Jenkins MK, Mueller DL. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic Thelper 1 cells. J Immunol. 1996; 157:2048-2057.
54. Kang SM, Beverly B, Tran AC, Brorson K, Schwartz RH, Lenardo MJ. Transactivation by AP-1 is a molecular target of T cell clonal anergy.Science. 1992;257:1134-1138.
55. Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, BrummerT. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immu no receptors. Eur J Immunol.2005;35:31-41.
56. Thompson LF, Van de Wiele CJ; Laurent AB, et al. Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deticient fetal thymic organ cultures. J Clin Invest. 2000;106:1149-1157.
57. Chan B, Wara D, Bastian J. et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117:133-143.
58. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol. 1995;76(suppl):S228-S232.